Schrödinger Scores Big Despite Q3 Miss As Novartis Collaboration Promises Billions In Milestones: Details

Schrodinger, Inc. (NASDAQ:SDGR) shares are trading higher on Tuesday. The company disclosed a research collaboration and license agreement with Novartis AG (NYSE:NVS) to advance multiple development candidates.

The companies also announced an extended three-year agreement that grants Novartis broad access to Schrödinger’s predictive modeling and informatics platform, enabling large-scale integration across research sites.

Karen Akinsanya, president of R&D, therapeutics at Schrödinger, said, “We are delighted to work with Novartis and leverage their strong expertise to jointly advance several of Schrödinger’s existing non-oncology discovery programs as well as collaborate on additional programs.”

Schrödinger will support full platform integration to enhance computational drug discovery for Novartis. As per the terms, Novartis will pay Schrödinger $150 million upfront, ...